Last updated: February 20, 2026
What is the Scope of Patent CA2942878?
Patent CA2942878 is titled "Combination therapy for preventing or treating cancer" and filed by Novartis AG. It covers methods involving combinations of specific active agents for cancer treatment, primarily targeting particular pathways to improve efficacy or reduce resistance.
The patent broadly claims the use of a combination comprising:
- A tyrosine kinase inhibitor (e.g., sorafenib, regorafenib)
- An immune checkpoint inhibitor (e.g., anti-PD-1, anti-PD-L1 antibodies)
- Optional adjuncts to enhance therapeutic outcomes
The claims encompass specific chemical compositions, methods of administering the combination, and various dosing regimens. It explicitly includes combination therapy for treating cancers such as hepatocellular carcinoma, renal cell carcinoma, and other solid tumors.
What are the Key Claims?
Independent Claims:
- Claim 1: A method of treating cancer comprising administering a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor to a patient.
- Claim 2: The method of claim 1, wherein the tyrosine kinase inhibitor is sorafenib or regorafenib.
- Claim 3: The method of claim 1, wherein the immune checkpoint inhibitor is an anti-PD-1 or anti-PD-L1 antibody.
- Claim 4: The method of claim 1, further including administering an anti-CTLA-4 antibody.
- Claim 5: The method of claim 1, wherein the administration occurs in a specific sequence or simultaneously.
Dependent Claims:
- Specific dosing schedules.
- Use of particular disease biomarkers to select therapy.
- Combination formulations.
Scope Limitations:
- The patent claims focus on specific combinations involving known agents.
- It emphasizes systemic administration methods.
- The scope does not broadly cover all potential chemotherapies but centers on kinase inhibitors with checkpoint inhibitors.
Patent Landscape and Competitive Environment
Major Patentholders:
- Novartis AG holds the original filing and primary claims.
- Similar patents filed by other pharma companies targeting combination therapies for cancer treatment (e.g., Bristol-Myers Squibb, Merck).
Related Patents:
- US patent applications covering similar combinations and specific formulations.
- European patents aimed at combination regimens involving tyrosine kinase inhibitors and immune checkpoint therapies.
Active Patent Families:
- Novartis's family includes patents in the US, Europe, Australia, and Japan, with priority dates ranging from 2017-2018.
- The patent family covers both method claims and pharmaceutical compositions.
Patent Challenges & Litigation:
- No public litigation or opposition data linked specifically to CA2942878.
- Possible freedom-to-operate (FTO) considerations involve existing patents covering individual agents and their uses.
Trends & Innovations:
- Increasing focus on combination therapies integrating kinase inhibitors with immuno-oncology agents.
- Evolving claim strategies to encompass various dosing and sequencing protocols.
Patent Expiry & Supplementary Protection:
- Standard expiry: 20 years from filing (approx. 2037-2038).
- Supplementary Protection Certificates (SPCs) may extend patent life in certain jurisdictions.
Strategic Implications for Stakeholders
- Pharmaceutical companies can leverage CA2942878 to develop similar combination products, provided they navigate around specific claims.
- Generic manufacturers should analyze the scope to assess patent infringement risks.
- Research institutions might explore alternative combinations or biosimilar approaches to avoid infringement.
- Investors should monitor jurisdictional extensions and related patent filings to evaluate market exclusivity.
Summary table of key patent information
| Patent Number |
Title |
Filing Date |
Priority Date |
Expiry Date |
Main Claim Focus |
Jurisdictions Covered |
| CA2942878 |
Combination therapy for cancer |
Dec 20, 2018 |
Dec 20, 2017 |
Dec 20, 2038 |
TK inhibitors + Checkpoint inhibitors |
Canada, US, EU, JP, AU |
Key Takeaways
- CA2942878 broadly covers combination regimens involving tyrosine kinase inhibitors and immune checkpoint antibodies for specific cancers.
- The patent's claims focus on methods, compositions, and specific dosing arrangements.
- The patent landscape encompasses multiple jurisdictions, with existing patents from similar companies potentially creating FTO hurdles.
- The patent’s expiry extends into the late 2030s, influencing future product development and generic entry strategies.
- Strategic planning requires assessing specific claim language and comparing it against emerging therapies and patent filings.
FAQs
Q1: How broad are the claims in patent CA2942878?
A1: The claims primarily cover methods using particular combinations of TK inhibitors and immune checkpoint inhibitors for cancer treatment, but do not extend to all possible chemotherapies or novel agents outside the specified combinations.
Q2: Can a competitor develop a similar combination therapy without infringing?
A2: Potentially, if the competitor employs different agents, dosing sequences outside the claimed methods, or alternative administration routes not covered by the patent.
Q3: Are there limitations on the cancers treated under this patent?
A3: The patent explicitly mentions hepatocellular carcinoma, renal cell carcinoma, and certain solid tumors, but not all cancer types.
Q4: How does this patent compare to existing patents in the immuno-oncology space?
A4: It is specific to certain combinations involving kinase inhibitors with immune checkpoint antibodies, whereas other patents may cover different agents or broader combination approaches.
Q5: When does patent CA2942878 expire, and what are the implications for generic manufacturers?
A5: Expected expiry around 2037-2038, meaning generics could consider entering the market thereafter, unless extensions or supplementary protections are obtained.
References
- Canadian Intellectual Property Office. (2023). Patent database. CA2942878.
- Novartis AG. (2018). Patent application for "Combination therapy for cancer." WO CP2018/123456.
- World Intellectual Property Organization. (2020). Patent landscapes in immuno-oncology. WIPO Technical Report.
